Raymond James & Associates’s CareTrust REIT CTRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $21.1M | Buy |
684,971
+65,756
| +11% | +$1.86M | 0.01% | 790 |
|
|
2024
Q2 | $15.5M | Sell |
619,215
-71,609
| -10% | -$1.77M | 0.01% | 908 |
|
|
2024
Q1 | $16.8M | Buy |
690,824
+26,937
| +4% | +$608K | 0.01% | 855 |
|
|
2023
Q4 | $14.9M | Buy |
663,887
+91,670
| +16% | +$2.03M | 0.01% | 872 |
|
|
2023
Q3 | $11.7M | Buy |
572,217
+374,593
| +190% | +$7.58M | 0.01% | 951 |
|
|
2023
Q2 | $3.92M | Buy |
197,624
+4,915
| +3% | +$96K | ﹤0.01% | 1643 |
|
|
2023
Q1 | $3.77M | Sell |
192,709
-312
| -0.2% | -$6.1K | ﹤0.01% | 1661 |
|
|
2022
Q4 | $3.59M | Sell |
193,021
-402,157
| -68% | -$7.51M | ﹤0.01% | 1647 |
|
|
2022
Q3 | $10.8M | Sell |
595,178
-44,065
| -7% | -$898K | 0.01% | 916 |
|
|
2022
Q2 | $11.8M | Buy |
639,243
+39,087
| +7% | +$693K | 0.01% | 885 |
|
|
2022
Q1 | $11.6M | Sell |
600,156
-163,178
| -21% | -$3.22M | 0.01% | 986 |
|
|
2021
Q4 | $17.4M | Sell |
763,334
-229,801
| -23% | -$4.87M | 0.01% | 817 |
|
|
2021
Q3 | $20.2M | Buy |
993,135
+391,708
| +65% | +$8.84M | 0.02% | 702 |
|
|
2021
Q2 | $14M | Sell |
601,427
-35,379
| -6% | -$833K | 0.01% | 892 |
|
|
2021
Q1 | $14.8M | Buy |
636,806
+80,147
| +14% | +$1.84M | 0.02% | 816 |
|
|
2020
Q4 | $12.3M | Buy |
556,659
+436,619
| +364% | +$8.6M | 0.01% | 837 |
|
|
2020
Q3 | $2.14M | Buy |
120,040
+53,823
| +81% | +$979K | ﹤0.01% | 1724 |
|
|
2020
Q2 | $1.14M | Sell |
66,217
-8,934
| -12% | -$156K | ﹤0.01% | 2075 |
|
|
2020
Q1 | $1.11M | Sell |
75,151
-61,679
| -45% | -$1.22M | ﹤0.01% | 1909 |
|
|
2019
Q4 | $2.82M | Sell |
136,830
-38,523
| -22% | -$843K | ﹤0.01% | 1614 |
|
|
2019
Q3 | $4.12M | Buy |
175,353
+727
| +0.4% | +$17.1K | 0.01% | 1334 |
|
|
2019
Q2 | $4.15M | Buy |
174,626
+29,534
| +20% | +$716K | 0.01% | 1331 |
|
|
2019
Q1 | $3.4M | Buy |
145,092
+95,771
| +194% | +$2.1M | 0.01% | 1417 |
|
|
2018
Q4 | $910K | Buy |
49,321
+1,036
| +2% | +$19.3K | ﹤0.01% | 2141 |
|
|
2018
Q3 | $855K | Buy |
48,285
+1,461
| +3% | +$25.7K | ﹤0.01% | 2352 |
|
|
2018
Q2 | $781K | Buy |
46,824
+11,894
| +34% | +$179K | ﹤0.01% | 2366 |
|
|
2018
Q1 | $468K | Sell |
34,930
-79,598
| -70% | -$1.18M | ﹤0.01% | 2605 |
|
|
2017
Q4 | $1.92M | Sell |
114,528
-11,586
| -9% | -$214K | ﹤0.01% | 1721 |
|
|
2017
Q3 | $2.4M | Sell |
126,114
-10,425
| -8% | -$195K | ﹤0.01% | 1524 |
|
|
2017
Q2 | $2.53M | Sell |
136,539
-6,125
| -4% | -$111K | 0.01% | 1417 |
|
|
2017
Q1 | $2.4M | Sell |
142,664
-6,184
| -4% | -$96K | 0.01% | 1423 |
|
|
2016
Q4 | $2.28M | Buy |
148,848
+17,589
| +13% | +$252K | 0.01% | 1406 |
|
|
2016
Q3 | $1.94M | Buy |
131,259
+29,409
| +29% | +$432K | 0.01% | 1472 |
|
|
2016
Q2 | $1.4M | Buy |
101,850
+71,700
| +238% | +$947K | ﹤0.01% | 1541 |
|
|
2016
Q1 | $383K | Buy |
30,150
+7,300
| +32% | +$80.9K | ﹤0.01% | 2194 |
|
|
2015
Q4 | $250K | Sell |
22,850
-39,233
| -63% | -$434K | ﹤0.01% | 2262 |
|
|
2015
Q3 | $705K | Buy |
+62,083
| New | +$752K | ﹤0.01% | 1772 |
|
Other funds holding CTRE
ZP
Raymond James & Associates's CTRE Position: Q3 2024 in Review
Raymond James & Associates increased its CareTrust REIT (CTRE) stake by 11% in Q3 2024, buying an estimated $1.86M and bringing the position to 684,971 shares worth $21.1M. The position accounts for 0.01% of the portfolio, ranked #790.
Raymond James & Associates first reported a position in CTRE in Q3 2015 and has held it in 37 quarters since. 348 funds tracked by Wall St. Rank hold CTRE as of Q3 2024.
- Raymond James & Associates held 684,971 shares of CareTrust REIT worth $21.1M as of Q3 2024.
- Raymond James & Associates bought 65,756 CareTrust REIT shares in Q3 2024, an estimated $1.86M.
- CareTrust REIT made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #790 holding.
- Raymond James & Associates first reported a position in CareTrust REIT in Q3 2015 and has held it in 37 quarters since.
- 348 funds tracked by Wall St. Rank held CareTrust REIT as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.